Table 1. Sociodemographic and clinical profile of regular† patients in 2021 (n=5365) aged 18+ with diabetes diagnosis and assessed for monitoring and control in 2022.
| Variables | Total | Urban | Inner regional | Rural | ||||
|---|---|---|---|---|---|---|---|---|
| (n=5365) | (n=1680) | (n=1462) | (n=2223) | |||||
| % | (95% CI) | % | (95% CI) | % | (95% CI) | % | (95% CI) | |
| Practice IRSAD quintiles | ||||||||
| Most advantaged | 6.4 | (4.0 to 10.2) | 16.6 | (11.0 to 24.1) | 1.6 | (0.7 to 3.4) | 1.8 | (0.3 to 10.3) |
| High | 9.4 | (5.6 to 15.3) | 16.5 | (11.8 to 22.8) | 3 | (1.1 to 8.2) | 7.9 | (2.2 to 25.0) |
| Middle | 33.7 | (19.4 to 51.8) | 23.9 | (16.0 to 34.1) | 31.1 | (18.1 to 48.0) | 42.8 | (16.3 to 74.3) |
| Low | 25.9 | (18.1 to 35.5) | 26.6 | (18.7 to 36.4) | 31.4 | (20.9 to 44.2) | 21.8 | (9.9 to 41.6) |
| Most disadvantaged | 24.6 | (16.5 to 35.1) | 16.4 | (10.1 to 25.5) | 32.9 | (21.2 to 47.1) | 25.6 | (12.1 to 46.4) |
| Gender | ||||||||
| Male | 41.9 | (40.3 to 43.6) | 41.5 | (38.9 to 44.1) | 41.7 | (38.7 to 44.8) | 42.4 | (40.0 to 44.9) |
| Female | 58.1 | (56.4 to 59.7) | 58.5 | (55.9 to 61.1) | 58.3 | (55.2 to 61.3) | 57.6 | (55.1 to 60.0) |
| Age group | ||||||||
| 18–34 | 11.3 | (10.0 to 12.8) | 14.2 | (12.1 to 16.7) | 11.6 | (9.5 to 14.0) | 9 | (7.6 to 10.5) |
| 35–49 | 21.7 | (20.2 to 23.2) | 21.2 | (19.1 to 23.4) | 21.6 | (19.1 to 24.4) | 22.1 | (19.8 to 24.6) |
| 50–64 | 36.8 | (34.0 to 39.7) | 34.8 | (31.9 to 37.8) | 34.3 | (31.6 to 37.0) | 40 | (35.6 to 44.5) |
| 65–74 | 19.2 | (17.5 to 21.0) | 18.7 | (16.5 to 21.1) | 20.1 | (17.9 to 22.5) | 19.1 | (16.0 to 22.6) |
| 75+ | 11 | (9.6 to 12.5) | 11.1 | (9.3 to 13.3) | 12.4 | (10.5 to 14.6) | 9.9 | (7.9 to 12.4) |
| IRSAD quintile | ||||||||
| Most advantaged | 6.2 | (4.2 to 9.3) | 15 | (10.8 to 20.5) | 1.3 | (0.6 to 3.0) | 2.7 | (0.8 to 8.6) |
| High | 10.2 | (8.1 to 12.8) | 18.3 | (14.8 to 22.5) | 5.1 | (3.4 to 7.5) | 7.3 | (3.7 to 13.8) |
| Middle | 25.7 | (19.5 to 33.0) | 25.5 | (20.4 to 31.3) | 27.8 | (18.2 to 39.9) | 24.6 | (13.1 to 41.4) |
| Low | 30.3 | (24.9 to 36.4) | 26.1 | (20.7 to 32.3) | 29.2 | (20.7 to 39.5) | 34.2 | (22.8 to 47.7) |
| Most disadvantaged | 27.5 | (23.0 to 32.6) | 15.1 | (10.6 to 21.0) | 36.6 | (27.7 to 46.6) | 31.2 | (22.9 to 41.0) |
| Smoking status | ||||||||
| Non-smoker | 34.7 | (32.8 to 36.6) | 36.8 | (33.9 to 39.8) | 33.9 | (30.0 to 38.1) | 33.5 | (31.0 to 36.0) |
| Ex-smoker | 31.9 | (30.1 to 33.8) | 30.3 | (27.7 to 33.1) | 34.2 | (30.7 to 37.9) | 31.7 | (28.9 to 34.8) |
| Smoker | 30.2 | (27.6 to 32.9) | 28.1 | (25.2 to 31.2) | 29 | (25.6 to 32.6) | 32.5 | (28.4 to 36.9) |
| Not stated/not recorded | 3.2 | (2.2 to 4.6) | 4.8 | (2.9 to 7.6) | 2.9 | (1.8 to 4.7) | 2.2 | (1.2 to 4.1) |
| Cardiovascular disease* | ||||||||
| Yes | 25.4 | (22.6 to 28.5) | 23.9 | (21.4 to 26.5) | 23.8 | (21.0 to 26.8) | 27.7 | (22.8 to 33.2) |
| Chronic kidney disease | ||||||||
| Yes | 15.3 | (13.3 to 17.4) | 12.5 | (10.8 to 14.4) | 15.3 | (13.3 to 17.6) | 17.4 | (14.2 to 21.0) |
*
Includes ischaemic heart disease, stroke, heart failure, peripheral arterial disease and aortic disease.
†
Regular patients: ≥3 consultations in 2020–2022, with at least one in each of these 3 years.
BMI, Body Mass Index; IRSAD, Index of Relative Socio-economic Advantage and Disadvantage.